Scarica l'app Stockscreener
9.62
3.12%
-0.31
Dopo l'orario di chiusura:
9.74
0.12
+1.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Biohaven Ltd Borsa (BHVN) Ultime notizie
Morgan Stanley Issues Pessimistic Forecast for Biohaven (NYSE:BHVN) Stock Price - MarketBeat
Stock market today: Dow Jones, S&P 500 futures slip after Christmas Day—Nvidia, Sobr Safe, Biohaven in focus - MSN
Biohaven Ltd. (NYSE:BHVN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Biohaven (NYSE:BHVN) Trading Down 8%Here's What Happened - MarketBeat
Biohaven (BHVN) Is Down 6.1% After Ending BHV-7000 Depression Trial To Refocus On Epilepsy And Obesity - simplywall.st
The Bull Case For Biohaven (BHVN) Could Change Following BHV-7000 MDD Trial Halt And R&D Pivot - Yahoo! Finance Canada
Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Biohaven (BHVN) Earnings Date and Reports 2026 - MarketBeat
Risk Check: Why Biohaven Ltd stock attracts global investorsLong Setup & Fast Exit and Entry Strategy Plans - moha.gov.vn
Breakout Move: Why Biohaven Ltd stock attracts global investorsJuly 2025 Catalysts & Low Drawdown Momentum Ideas - moha.gov.vn
Wall Street analysts predict an 88.57% upside in Biohaven Ltd. (BHVN): Here's what you should know - MSN
Biohaven reports Phase 2 depression trial results - Indian Pharma Post
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail
(BHVN) Risk Channels and Responsive Allocation - Stock Traders Daily
Biohaven (NYSE:BHVN) Trading 3.6% HigherHere's What Happened - MarketBeat
Analysts Conflicted on These Healthcare Names: Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail
Biohaven Shares Rally as Promising Cancer Data Unveiled - StocksToTrade
Biohaven Reports Promising Results for Cancer Treatment, Faces Setback in Depression Therapy - StocksToTrade
Biohaven’s BHV-1510 Promising Cancer Data Fuels Market Anticipation - timothysykes.com
Biohaven Emerges Strong Amid Promising Cancer Drug Data - timothysykes.com
Key facts: Biohaven Ltd. develops BHV-7000 for epilepsy; J.P. Morgan reports poor trial results - TradingView — Track All Markets
What's Going On With Biohaven Stock Friday? - Benzinga
Biohaven (NYSE:BHVN) Shares Gap DownWhat's Next? - MarketBeat
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology - FinancialContent
Biohaven Stock Gaps Lower on Failed Phase 2 Drug Trial - Schaeffer's Investment Research
US Stocks Mixed; Biohaven Shares Fall - Sahm
Watch Nvidia Up on AI Licensing Deal, Biohaven Down on Study Results, Coforge Up - Bloomberg.com
Stock Market Today: Dow Jones, S&P 500, Nasdaq Futures Decline After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus (UPDATED) - Benzinga
Stock Market Today: Dow Jones, S&P 500, Nasdaq Futures Decline After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus (UPDATED) - Benzinga
Cautiously Bullish After Biohaven’s Cash Runway And Dilution Risk Rise (NYSE:BHVN) - Seeking Alpha
Stock Movers: Nvidia, Coforge, Biohaven - Bloomberg.com
Stifel reiterates Buy rating on Xenon Pharmaceuticals stock amid competitor setback - Investing.com
Biohaven Misses The Mark In Depression Trial, Stock Falls - Benzinga
H.C. Wainwright maintains Biohaven stock at Neutral after MDD trial failure - Investing.com Nigeria
Biohaven, Omeros And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Biohaven downgraded to Market Perform from Outperform at Bernstein - MSN
Biohaven stock defended despite trial setback (BHVN:NYSE) - Seeking Alpha
Stock Market Today: Dow Jones, S&P 500 Futures Slip After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus - Sahm
Why Davis Commodities Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Nvidia, Sobr Safe And 3 Stocks To Watch Heading Into Friday - Benzinga
Analysts Are Neutral on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Omeros (OMER) - The Globe and Mail
Biohaven (BHVN) Valuation Check After BHV-1510 Cancer Data and BHV-7000 Pipeline Shift - simplywall.st
Biohaven Shares Dive: Time to Reflect? - StocksToTrade
Biohaven’s depression drug misses primary endpoint in Phase 2 study By Investing.com - Investing.com Nigeria
Biohaven's depression drug fails mid-stage trial, shares fall - marketscreener.com
Biohaven Stock Slumps After Hours As Failed Depression Study Adds To A Brutal 2025 — Retail Eyes Epilepsy And Obesity Catalysts - Stocktwits
Biohaven Provides Update From Phase 2 Proof-of-Concept Study wit - GuruFocus
Biohaven (NYSE:BHVN) Stock Price Down 13%What's Next? - MarketBeat
Biohaven’s depression drug misses primary endpoint in Phase 2 study - Investing.com India
Biohaven stock falls after depression drug misses primary endpoint By Investing.com - Investing.com Nigeria
Biohaven falls as depression candidate fails in phase 2 - Seeking Alpha
Biohaven stock falls after depression drug misses primary endpoint - Investing.com
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder - PR Newswire
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):